Open with the concentration pattern: therapeutic antibodies are the most IP-dense drug class, and Genentech sits at the center of it. Across the antibody record — anti-VEGF antibodies, antibody-drug conjugates, and antibody-engineering more broadly — Genentech is consistently the largest single assignee, with grants like US9777059B2 ("Anti-VEGF antibodies," 2017; CPC C07K 16/22) representing its foundational holdings. Regeneron, Novartis, Bristol-Myers Squibb, and Xencor populate the next tier.
What the assignee distribution signals strategically: a pioneer-plus-tail structure. One dominant early assignee with a deep estate, followed by a long tail of specialists who file on specific antigens, specific antibody formats (full IgG, Fab fragments, bispecifics), and specific conjugates. This is different from the CRISPR landscape, where the foundation is institutional; in antibodies the foundation is substantially corporate, which changes the licensing dynamics — you are more often negotiating with a competitor than with a university tech-transfer office.
The format axis matters for mapping. The C07K record splits by antibody format: full monoclonal antibodies, antigen-binding fragments (the SinoCellTech Fab grant US12479911B2 is an example), bispecifics, and antibody-drug conjugates. Each format is a sub-landscape with its own dense filings. A portfolio map that treats "antibodies" as one field misses that an anti-VEGF Fab and an anti-VEGF full IgG occupy different claim space even against the same target.
Filing velocity in the antibody record has been high and sustained for two decades, with the ADC sub-field especially active — the antibody-drug-conjugate record alone runs to tens of thousands of grants. Sustained high velocity in a pioneer-anchored field is the signature of a mature, crowded landscape where genuine white space is scarce and most new value comes from novel targets or novel formats rather than foundational claims.
Distinguish thicket from moat at the field level. Genentech's anti-VEGF position looks more like a genuine foundational holding (a pioneer estate on a major target) than a mere thicket; the surrounding specialist filings on humanized variants, fragments, and conjugates are thicket. So the field combines a corporate foundation with a defensive thicket — the freedom-to-operate analysis must clear both the pioneer's broad claims and the relevant specialist's narrow ones.
The strategist's conclusion: read the C07K antibody landscape as Genentech-anchored, with a corporate foundation rather than an institutional one, and a long tail of format- and target-specific filings. The concentration tells you who you negotiate with; the format axis tells you where the sub-landscapes are; and the sustained velocity tells you the white space is in new targets and engineered formats, not in the foundational antibody claims that the pioneers already hold.